Meta to Layoff 20%, AI Cured Dogs Cancer, Nvidia's New Chip

The episode opens with a breakthrough in AI‑driven personalized medicine: a tech entrepreneur used ChatGPT, AlphaFold and mRNA design tools to create a custom vaccine for his dog, Rosie. Within three months the tumor shrank by roughly 75%, showcasing how rapid AI workflows can accelerate experimental therapies. While regulatory hurdles still slow human applications, the case illustrates a tangible preview of AI‑powered oncology that could reshape drug development pipelines and patient‑specific treatments.

Next, the host highlights Nvidia’s upcoming AI chip launch at GTC, emphasizing the shift from model training to massive inference deployment across enterprises. The new silicon is positioned to handle next‑generation large‑scale models, lowering latency and energy costs for real‑time AI services. As inference demand explodes, Nvidia’s generational performance jumps reset industry benchmarks, reinforcing its role as the backbone of the expanding AI infrastructure market.

Finally, the discussion turns to corporate strategy, noting Meta’s rumored 20% workforce reduction to fund an $115‑$135 billion AI capex plan, alongside OpenAI’s $10 billion joint venture with private‑equity giants like TPG and Bain Capital. These moves signal a broader trend: AI is becoming the primary driver of both investment and restructuring, prompting layoffs, new venture models, and accelerated adoption across thousands of portfolio companies. The episode concludes that the AI era is no longer emerging—it’s reshaping talent, capital allocation, and competitive dynamics across the tech sector.